

TAK-659

Chemical Properties


CAS No. : 1312691-33-0

Formula: C₁₇H₂₁FN₆O

Molecular Weight: 344.39

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	TAK-659 is a spleen tyrosine kinase (SYK) inhibitor.
Targets(IC50)	Others,FLT,Syk

Solubility Information

Solubility	DMSO: Soluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.9037 mL	14.5184 mL	29.0368 mL
5 mM	0.5807 mL	2.9037 mL	5.8074 mL
10 mM	0.2904 mL	1.4518 mL	2.9037 mL
50 mM	0.0581 mL	0.2904 mL	0.5807 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cen O, Kannan K, Huck Sappal J, Yu J, Zhang M, Arian M, Ucur A, Ustek D, Cen Y, Gordon L, Longnecker R. Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma. *mSphere*. 2018 Aug 22;3(4). pii: e00378-18. doi: 10.1128/mSphereDirect.00378-18. PubMed PMID: 30135222; PubMed Central PMCID: PMC6106053.

Lee SJ, Choi JS, Bong SM, Hwang HJ, Lee J, Song HJ, Lee J, Kim JH, Koh JS, Lee BI. Crystal Structures of Spleen Tyrosine Kinase in Complex with Two Novel 4-Aminopyrido[4,3-d] Pyrimidine Derivative Inhibitors. *Mol Cells*. 2018 Jun;41(6): 545-552. doi: 10.14348/molcells.2018.2219. Epub 2018 Jun 12. PubMed PMID: 29890824; PubMed Central PMCID: PMC6030240.

Liu D, Mamorska-Dyga A. Syk inhibitors in clinical development for hematological malignancies. *J Hematol Oncol*. 2017 Jul 28;10(1):145. doi: 10.1186/s13045-017-0512-1. Review. PubMed PMID: 28754125; PubMed Central PMCID: PMC5534090.

Purroy N, Carabia J, Abrisqueta P, Egia L, Aguiló M, Carpio C, Palacio C, Crespo M, Bosch F. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. *Oncotarget*. 2017 Jan 3;8(1):742-756. doi: 10.18632/oncotarget.13557. PubMed PMID: 27888629; PubMed Central PMCID: PMC5352193.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481